Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Obesity

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 85 articles:
HTML format



Single Articles


    January 2025
  1. HORTON R
    Offline: Making obesity matter.
    Lancet. 2025;405:284.
    PubMed    


  2. KLOPPENBURG M, Namane M, Cicuttini F
    Osteoarthritis.
    Lancet. 2025;405:71-85.
    PubMed     Abstract available


    November 2024
  3. KIRBY T
    Brazil considers obesity discrimination law.
    Lancet. 2024;404:1912-1913.
    PubMed    


  4. SEBERT S
    The obesity crisis in the USA: why are there no signs of plateauing yet?
    Lancet. 2024 Nov 12:S0140-6736(24)02467-X. doi: 10.1016/S0140-6736(24)02467.
    PubMed    



  5. National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050.
    Lancet. 2024 Nov 12:S0140-6736(24)01548-4. doi: 10.1016/S0140-6736(24)01548.
    PubMed     Abstract available


    October 2024
  6. EZZATI M, Zhou B, Bennett JE, Phelps NH, et al
    Assessing worldwide trends of underweight and obesity - Authors' reply.
    Lancet. 2024;404:1644.
    PubMed    


  7. BOMBAK A, Riediger N
    Assessing worldwide trends of underweight and obesity.
    Lancet. 2024;404:1643.
    PubMed    


  8. CHRISTENSEN DL, Bygbjerg IC
    Assessing worldwide trends of underweight and obesity.
    Lancet. 2024;404:1642.
    PubMed    


  9. CZERNICHOW S, Ziegler O, Clement K, Coupaye M, et al
    Assessing worldwide trends of underweight and obesity.
    Lancet. 2024;404:1642-1643.
    PubMed    


  10. VAN STEIJVOORT E, Borry P
    Assessing worldwide trends of underweight and obesity.
    Lancet. 2024;404:1641-1642.
    PubMed    


    August 2024

  11. General and abdominal adiposity and hypertension in eight world regions: a pooled analysis of 837 population-based studies with 7.5 million participants.
    Lancet. 2024;404:851-863.
    PubMed     Abstract available


  12. NASIR K
    Embracing the duality of BMI and central adiposity.
    Lancet. 2024;404:824-825.
    PubMed    


  13. KOSIBOROD MN, Deanfield J, Pratley R, Borlaug BA, et al
    Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
    Lancet. 2024 Aug 29:S0140-6736(24)01643-X. doi: 10.1016/S0140-6736(24)01643.
    PubMed     Abstract available


  14. DEANFIELD J, Verma S, Scirica BM, Kahn SE, et al
    Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
    Lancet. 2024;404:773-786.
    PubMed     Abstract available


  15. LINGVAY I, Cohen RV, Roux CWL, Sumithran P, et al
    Obesity in adults.
    Lancet. 2024 Aug 16:S0140-6736(24)01210-8. doi: 10.1016/S0140-6736(24)01210.
    PubMed     Abstract available


    May 2024
  16. MORIN-PAPUNEN L
    Bariatric surgery in women with PCOS and obesity.
    Lancet. 2024 May 20:S0140-6736(24)00811-0. doi: 10.1016/S0140-6736(24)00811.
    PubMed    


  17. SAMARASINGHE SNS, Leca B, Alabdulkader S, Dimitriadis GK, et al
    Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial.
    Lancet. 2024 May 20:S0140-6736(24)00538-5. doi: 10.1016/S0140-6736(24)00538.
    PubMed     Abstract available


    April 2024
  18. THE LANCET EDITORS
    Retraction and republication-Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
    Lancet. 2024;403:1321.
    PubMed    


  19. SHI Q, Wang Y, Hao Q, Vandvik PO, et al
    Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
    Lancet. 2024;403:e21-e31.
    PubMed     Abstract available


  20. BUTLER J, Shah SJ, Petrie MC, Borlaug BA, et al
    Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
    Lancet. 2024 Apr 4:S0140-6736(24)00469-0. doi: 10.1016/S0140-6736(24)00469.
    PubMed     Abstract available


  21. DONAL E, L'Official G, Istratoaie S
    Semaglutide-a new treatment for obesity-related heart failure with preserved ejection fraction?
    Lancet. 2024 Apr 4:S0140-6736(24)00653-6. doi: 10.1016/S0140-6736(24)00653.
    PubMed    


    March 2024
  22. JOHANSSON K, Bodnar LM, Stephansson O, Abrams B, et al
    Safety of low weight gain or weight loss in pregnancies with class 1, 2, and 3 obesity: a population-based cohort study.
    Lancet. 2024 Mar 28:S0140-6736(24)00255-1. doi: 10.1016/S0140-6736(24)00255.
    PubMed     Abstract available


  23. GAILLARD R
    Optimising gestational weight gain among pregnant women with obesity.
    Lancet. 2024 Mar 28:S0140-6736(24)00470-7. doi: 10.1016/S0140-6736(24)00470.
    PubMed    


    February 2024
  24. TUMAS N, Lopez SR
    Double burden of underweight and obesity: insights from new global evidence.
    Lancet. 2024 Feb 29:S0140-6736(24)00051-5. doi: 10.1016/S0140-6736(24)00051.
    PubMed    



  25. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults.
    Lancet. 2024 Feb 29:S0140-6736(23)02750-2. doi: 10.1016/S0140-6736(23)02750.
    PubMed     Abstract available


  26. CAMPBELL P, Rutten FH, Lee MM, Hawkins NM, et al
    Heart failure with preserved ejection fraction: everything the clinician needs to know.
    Lancet. 2024 Feb 14:S0140-6736(23)02756-3. doi: 10.1016/S0140-6736(23)02756.
    PubMed     Abstract available


    January 2024
  27. THE LANCET
    Treating obesity and diabetes: drugs alone are not enough.
    Lancet. 2024;403:1.
    PubMed    


    December 2023
  28. DANIELS JP
    Colombia introduces junk food tax.
    Lancet. 2023;402:2062.
    PubMed    


    November 2023
  29. ZOU M, Northstone K, Leary S
    Causal effects of later-eating rhythm on adiposity in children through the comparison of two cohorts in the UK and China: a cross-cohort study.
    Lancet. 2023;402 Suppl 1:S99.
    PubMed     Abstract available


  30. ALRUBAIAN F, Mulla Z
    Governments policy measures to address obesity among adults: a scoping review of the global evidence.
    Lancet. 2023;402 Suppl 1:S20.
    PubMed     Abstract available


  31. CISNEROS AB, Headings R, Wells R, Reynolds C, et al
    Understanding the use of media analysis in public health research through food tax debates (HEALTHEI Project): a scoping review.
    Lancet. 2023;402 Suppl 1:S9.
    PubMed     Abstract available


  32. SPAVIN A, Moore A, Lunn J, Tucker F, et al
    Reflecting on parental insights into healthy lifestyles: a qualitative study.
    Lancet. 2023;402 Suppl 1:S85.
    PubMed     Abstract available


  33. CHEN S, Kuper H
    Tracing the temporal trends of modifiable risk factors in dementia: insights from the English Longitudinal Study of Ageing (2004-2019).
    Lancet. 2023;402 Suppl 1:S34.
    PubMed     Abstract available


  34. WALSH S, Wallace L, Kuhn I, Mytton O, et al
    Population-level interventions for the primary prevention of dementia: a complex evidence review.
    Lancet. 2023;402 Suppl 1:S13.
    PubMed     Abstract available


    October 2023
  35. KOTANI T, Tano S
    Long-term effects of gestational weight gain on mortality.
    Lancet. 2023 Oct 19:S0140-6736(23)01837-8. doi: 10.1016/S0140-6736(23)01837.
    PubMed    


  36. HINKLE SN, Mumford SL, Grantz KL, Mendola P, et al
    Gestational weight change in a diverse pregnancy cohort and mortality over 50 years: a prospective observational cohort study.
    Lancet. 2023 Oct 19:S0140-6736(23)01517-9. doi: 10.1016/S0140-6736(23)01517.
    PubMed     Abstract available


    September 2023
  37. SUMITHRAN P, Finucane FM, Cohen RV
    Obesity drug shortages are symptomatic of wider malaise.
    Lancet. 2023 Sep 29:S0140-6736(23)01963-3. doi: 10.1016/S0140-6736(23)01963.
    PubMed    


    June 2023
  38. GARVEY WT, Frias JP, Jastreboff AM, le Roux CW, et al
    Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Lancet. 2023 Jun 26:S0140-6736(23)01200-X. doi: 10.1016/S0140-6736(23)01200.
    PubMed     Abstract available


  39. APOVIAN CM, McDonnell ME
    CagriSema and the link between obesity and type 2 diabetes.
    Lancet. 2023 Jun 23:S0140-6736(23)01291-6. doi: 10.1016/S0140-6736(23)01291.
    PubMed    


  40. KNOP FK, Aroda VR, do Vale RD, Holst-Hansen T, et al
    Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2023 Jun 23:S0140-6736(23)01185-6. doi: 10.1016/S0140-6736(23)01185.
    PubMed     Abstract available


  41. FALLOWS E, Ells L, Anand V
    Semaglutide and the future of obesity care in the UK.
    Lancet. 2023 Jun 5:S0140-6736(23)01083-8. doi: 10.1016/S0140-6736(23)01083.
    PubMed    


    May 2023
  42. SKYLE D
    Fatima Cody Stanford: changing the narrative on obesity.
    Lancet. 2023;401:1644.
    PubMed    


    April 2023
  43. MAHGOUB S, Newsome PN
    Bariatric-metabolic surgery versus lifestyle intervention in non-alcoholic steatohepatitis.
    Lancet. 2023 Apr 20:S0140-6736(23)00773-0. doi: 10.1016/S0140-6736(23)00773.
    PubMed    


  44. VERRASTRO O, Panunzi S, Castagneto-Gissey L, De Gaetano A, et al
    Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial.
    Lancet. 2023 Apr 20:S0140-6736(23)00634-7. doi: 10.1016/S0140-6736(23)00634.
    PubMed     Abstract available


    February 2023
  45. PERDOMO CM, Cohen RV, Sumithran P, Clement K, et al
    Contemporary medical, device, and surgical therapies for obesity in adults.
    Lancet. 2023 Feb 9:S0140-6736(22)02403-5. doi: 10.1016/S0140-6736(22)02403.
    PubMed     Abstract available


    December 2022
  46. KRAMER CK, Leitao CB, Viana LV
    The impact of urbanisation on the cardiometabolic health of Indigenous Brazilian peoples: a systematic review and meta-analysis, and data from the Brazilian Health registry.
    Lancet. 2022;400:2074-2083.
    PubMed     Abstract available


    November 2022
  47. KRENZ K, McEachan R, Subiza-Perez M, Watmuff A, et al
    Exploring relationships between exposure to fast food outlets and childhood obesity at differing spatial resolutions: results from the Born in Bradford cohort study.
    Lancet. 2022;400 Suppl 1:S55.
    PubMed     Abstract available


  48. HESLEHURST N, Evans EH, Rodriguez ACI, Nagpal TS, et al
    Newspaper media framing of maternal obesity in the UK: a review and framework synthesis.
    Lancet. 2022;400 Suppl 1:S48.
    PubMed     Abstract available


  49. BIJLANI C, Vrinten C, Chang K, Hrobonova E, et al
    Changes in diet and physical activity after a pilot intervention to tackle childhood obesity in a deprived inner-London community: an observational cohort study.
    Lancet. 2022;400 Suppl 1:S22.
    PubMed     Abstract available


  50. BEYNON C
    Exploring the association between obesity and problems with peer relationships in children: a nationally representative cross-sectional study.
    Lancet. 2022;400 Suppl 1:S21.
    PubMed     Abstract available


    October 2022
  51. URVA S, Coskun T, Loh MT, Du Y, et al
    LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
    Lancet. 2022 Oct 27. pii: S0140-6736(22)02033.
    PubMed     Abstract available


    July 2022
  52. ABU DAYYEH BK, Bazerbachi F, Vargas EJ, Sharaiha RZ, et al
    Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial.
    Lancet. 2022 Jul 28. pii: S0140-6736(22)01280.
    PubMed     Abstract available


    June 2022
  53. GOLUBIC R, Barber TM, Caleyachetty R
    Obesity definition for personalised treatment of type 2 diabetes.
    Lancet. 2022;399:2189.
    PubMed    


  54. LINGVAY I, Sumithran P, Cohen RV, Roux CWL, et al
    Obesity definition for personalised treatment of type 2 diabetes Authors' reply.
    Lancet. 2022;399:2189-2190.
    PubMed    


  55. SHI Q, Wang Y, Li S
    Pharmacotherapy for adults with overweight and obesity - Authors' reply.
    Lancet. 2022;399:2101.
    PubMed    


  56. DAYYEH BKA
    Adjustable intragastric balloon for obesity - Author's reply.
    Lancet. 2022;399:2100.
    PubMed    


  57. STURGISS E, Ball L, Blane D, Hennessy M, et al
    Pharmacotherapy for adults with overweight and obesity.
    Lancet. 2022;399:2100-2101.
    PubMed    


  58. CHARALAMPAKIS V, Rajeev Y, Singhal R
    Adjustable intragastric balloon for obesity.
    Lancet. 2022;399:2099.
    PubMed    


  59. BRUNALDI VO, Neto MG
    Adjustable intragastric balloon for obesity.
    Lancet. 2022;399:2099.
    PubMed    


    April 2022
  60. CROSBIE EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, et al
    Endometrial cancer.
    Lancet. 2022;399:1412-1428.
    PubMed     Abstract available


    February 2022
  61. TATUM M
    China's population peak.
    Lancet. 2022;399:509.
    PubMed    


    December 2021
  62. SHI Q, Wang Y, Hao Q, Vandvik PO, et al
    Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
    Lancet. 2021 Dec 8. pii: S0140-6736(21)01640.
    PubMed     Abstract available


    November 2021
  63. LAU DCW, Erichsen L, Francisco AM, Satylganova A, et al
    Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
    Lancet. 2021 Nov 16. pii: S0140-6736(21)01751.
    PubMed     Abstract available


  64. ABU DAYYEH BK, Maselli DB, Rapaka B, Lavin T, et al
    Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial.
    Lancet. 2021 Nov 15. pii: S0140-6736(21)02394.
    PubMed     Abstract available


  65. SUDLOW A, le Roux CW
    Improving gastric balloons to treat obesity.
    Lancet. 2021 Nov 15. pii: S0140-6736(21)02505.
    PubMed    


    September 2021
  66. LINGVAY I, Sumithran P, Cohen RV, le Roux CW, et al
    Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation.
    Lancet. 2021 Sep 30. pii: S0140-6736(21)01919.
    PubMed     Abstract available


    August 2021
  67. MEGHJI J, Mortimer K, Jayasooriya S, Marks GB, et al
    Lung health in LMICs: tackling challenges ahead - Authors' reply.
    Lancet. 2021;398:490.
    PubMed    


  68. NEMERY B, Katoto PDMC, Develtere P
    Lung health in LMICs: tackling challenges ahead.
    Lancet. 2021;398:489-490.
    PubMed    


  69. KHOO EM, Li D, Ungan M, Jordan R, et al
    Lung health in LMICs: tackling challenges ahead.
    Lancet. 2021;398:488-489.
    PubMed    


    July 2021
  70. TEUFEL F, Seiglie JA, Geldsetzer P, Theilmann M, et al
    Body-mass index and diabetes risk in 57 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 685 616 adults.
    Lancet. 2021;398:238-248.
    PubMed     Abstract available


  71. WANG L, Zhou B, Zhao Z, Yang L, et al
    Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004-18.
    Lancet. 2021;398:53-63.
    PubMed     Abstract available


  72. FLEGAL KM
    BMI and obesity trends in Chinese national survey data.
    Lancet. 2021;398:5-7.
    PubMed    


  73. SALAH RO, Ghandour R, Husseini A
    Prevalence of overweight, obesity, and associated factors among adolescents in the occupied Palestinian territory: a cross-sectional study.
    Lancet. 2021;398 Suppl 1:S46.
    PubMed     Abstract available


    June 2021
  74. TREASURE J, Ambwani S
    Addressing weight stigma and anti-obesity rhetoric in policy changes to prevent eating disorders.
    Lancet. 2021 Jun 3. pii: S0140-6736(21)01109.
    PubMed    


    May 2021
  75. MINGRONE G, Bornstein SR
    Gain in survival after metabolic-bariatric surgery.
    Lancet. 2021;397:1785-1787.
    PubMed    


  76. ENEBO LB, Berthelsen KK, Kankam M, Lund MT, et al
    Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial.
    Lancet. 2021;397:1736-1748.
    PubMed     Abstract available


  77. SYN NL, Cummings DE, Wang LZ, Lin DJ, et al
    Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants.
    Lancet. 2021 May 6. pii: S0140-6736(21)00591.
    PubMed     Abstract available


    April 2021
  78. BECERRIL S, Fruhbeck G
    Cagrilintide plus semaglutide for obesity management.
    Lancet. 2021 Apr 22. pii: S0140-6736(21)00944.
    PubMed    


    March 2021
  79. LATINI R, Staszewsky L
    Semaglutide and effective weight control.
    Lancet. 2021;397:942-943.
    PubMed    


  80. DAVIES M, Faerch L, Jeppesen OK, Pakseresht A, et al
    Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
    Lancet. 2021 Mar 2. pii: S0140-6736(21)00213.
    PubMed     Abstract available


    November 2020
  81. CHAN JCN, Lim LL, Wareham NJ, Shaw JE, et al
    The Lancet Commission on diabetes: using data to transform diabetes care and patient lives.
    Lancet. 2020 Nov 12. pii: S0140-6736(20)32374.
    PubMed    


    September 2020
  82. HAWKES C, Ruel M, Wells JC, Popkin BM, et al
    The double burden of malnutrition-further perspective - Authors' reply.
    Lancet. 2020;396:815-816.
    PubMed    


  83. STEWART CP, de Pee S, Maleta K, Michaelsen KF, et al
    The double burden of malnutrition-further perspective.
    Lancet. 2020;396:814-815.
    PubMed    


  84. OSENDARP SJM, Brown KH, Neufeld LM, Udomkesmalee E, et al
    The double burden of malnutrition-further perspective.
    Lancet. 2020;396:813.
    PubMed    


  85. HOSSAIN MS, Ferdous S, Raheem E, Siddiqee MH, et al
    The double burden of malnutrition-further perspective.
    Lancet. 2020;396:813-814.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Obesity is free of charge.